Up to a quarter of ELANEmut SCN cases on long-term, moderate- or high-dose G-CSF therapy develop somatic CSF3R-activating mutations preceding the onset of MDS/AML (9), underscoring the need to investigate alternative therapies that could decrease therapeutic reliance on G-CSF. This evidence concerns the gene CSF3 and myelodysplastic syndrome.